Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Compassionate use study of Human MEsenchymal Stem Cell (MSC) for Hypoplastic Left Heart Syndrome (HLHS)

Next Previous
Trial Profile

Compassionate use study of Human MEsenchymal Stem Cell (MSC) for Hypoplastic Left Heart Syndrome (HLHS)

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 18 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Laromestrocel (Primary)
  • Indications Hypoplastic left heart syndrome
  • Focus Therapeutic Use

Most Recent Events

  • 18 Mar 2021 New trial record
  • 11 Mar 2021 According to a Longeveron media release, Dr. Kaushal was the first surgeon in the United States to administer allogeneic MSCs to a baby with HLHS
  • 11 Mar 2021 According to a Longeveron media release, e U.S. Food & Drug Administration (FDA) has granted expanded access approval for the administration of Longever's investigational cell therapy Lomecel-B to a child with Hypoplastic Left Heart Syndrome (HLHS).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top